Shopping Cart
- Remove All
Your shopping cart is currently empty
INCB 3284 is an orally available, selective and high affinity chemokine receptor 2 (CCR2) antagonist that inhibits monocyte chemotactic protein 1 from interacting with hCCR2.INCB 3284 is used in the study of hemorrhagic shock.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $33 | In Stock | |
| 5 mg | $51 | In Stock | |
| 10 mg | $81 | In Stock | |
| 25 mg | $137 | In Stock | |
| 50 mg | $196 | In Stock | |
| 100 mg | $296 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $80 | In Stock |
| Description | INCB 3284 is an orally available, selective and high affinity chemokine receptor 2 (CCR2) antagonist that inhibits monocyte chemotactic protein 1 from interacting with hCCR2.INCB 3284 is used in the study of hemorrhagic shock. |
| Targets&IC50 | MCP-1-hCCR2:3.7 nM, K+ channel (hERG):84 μM |
| In vitro | INCB3284 exhibited an IC50 of 3.7 nM for antagonizing the binding of monocyte chemoattractant protein-1 to hCCR2, an IC50 of 4.7 nM for antagonizing chemotactic activity, and an IC50 of 84 μM for inhibiting hERG potassium currents[1]. |
| In vivo | INCB 3284 (1 mg/kg/day, intraperitoneal injection) or C021 significantly improved the neurological outcomes in AOM-treated mice, reduced microglial activation, decreased phosphorylation of ERK1/2, and attenuated the upregulation of cytokines induced by AOM[2]. |
| Molecular Weight | 520.54 |
| Formula | C26H31F3N4O4 |
| Cas No. | 887401-92-5 |
| Smiles | COc1ccc(cn1)[C@@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F |
| Relative Density. | 1.35 g/cm3 (Predicted) |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 0.1 mg/mL (insoluble) DMSO: 60 mg/mL (115.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.84 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.